HSBC Holdings
VIR icon

HSBC Holdings’s Vir Biotechnology VIR Stock Holding History

HSBC Holdings’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$249K Sell
27,736
-3,174
-10% -$25.3K ﹤0.01% 2526
2025
Q4 		$182K Sell
30,910
-26,685
-46% -$159K ﹤0.01% 2706
2025
Q3 		$323K Buy
57,595
+13,269
+30% +$67.8K ﹤0.01% 2302
2025
Q2 		$229K Buy
44,326
+30,077
+211% +$161K ﹤0.01% 2613
2025
Q1 		$91.1K Sell
14,249
-12,060
-46% -$107K ﹤0.01% 2824
2024
Q4 		$192K Buy
+26,309
New +$208K ﹤0.01% 2732
2024
Q3 		– Sell
-46,222
Closed -$405K – 3168
2024
Q2 		$405K Buy
46,222
+27,605
+148% +$265K ﹤0.01% 2096
2024
Q1 		$189K Sell
18,617
-3,109
-14% -$31.7K ﹤0.01% 2707
2023
Q4 		$219K Buy
21,726
+5,655
+35% +$51.7K ﹤0.01% 2429
2023
Q3 		$151K Buy
+16,071
New +$229K ﹤0.01% 2485
2022
Q4 		– Sell
-13,776
Closed -$270K – 3200
2022
Q3 		$270K Sell
13,776
-2,696
-16% -$68.5K ﹤0.01% 2472
2022
Q2 		$422K Buy
+16,472
New +$385K ﹤0.01% 2435
2022
Q1 		– Sell
-8,634
Closed -$362K – 3502
2021
Q4 		$362K Buy
+8,634
New +$338K ﹤0.01% 2655

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

HSBC Holdings's VIR Position: Q1 2026 in Review

HSBC Holdings reduced its Vir Biotechnology (VIR) stake by 10% in Q1 2026, selling an estimated $25.3K and leaving 27,736 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

HSBC Holdings first reported a position in VIR in Q4 2021 and has held it in 13 quarters since. The position peaked at $422K in Q2 2022. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • HSBC Holdings held 27,736 shares of Vir Biotechnology worth $249K as of Q1 2026.
  • HSBC Holdings sold 3,174 Vir Biotechnology shares in Q1 2026, an estimated $25.3K.
  • Vir Biotechnology made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2526 holding.
  • HSBC Holdings first reported a position in Vir Biotechnology in Q4 2021 and has held it in 13 quarters since.
  • HSBC Holdings's Vir Biotechnology position peaked at $422K in Q2 2022.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.